Stereochemistry of mephedrone neuropharmacology: Enantiomer-specific behavioural and neurochemical effects in rats

British Journal of Pharmacology

Volumn 172, Issue 3, 2015, Pages 883-894

  Gregg, Ryan A ^a   Baumann, Michael H ^b   Partilla, John S ^b   Bonano, Julie S ^c   Vouga, Alexandre ^a   Tallarida, Christopher S ^a   Velvadapu, Venkata ^d   Smith, Garry R ^d   Peet, M Melissa ^e   Reitz, Allen B ^d   Negus, S Stevens ^c   Rawls, Scott M ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d Department of Pharmacology and Toxicology Virginia Commonwealth University ^*  (United States)

^e WESTERN MICHIGAN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4' METHYLMETHCATHINONE; DOPAMINE TRANSPORTER; SEROTONIN TRANSPORTER; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; METHAMPHETAMINE;

ACUTE DRUG ADMINISTRATION; ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN SYNAPTOSOME; COMPULSION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ABUSE; ENANTIOMER; FACILITATION; IN VITRO STUDY; LOCOMOTION; MALE; MOTOR ACTIVITY; NEUROTRANSMITTER RELEASE; NONHUMAN; PLACE PREFERENCE; RAT; REPEATED DRUG DOSE; REWARD; SELF STIMULATION; SENSITIZATION; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL BEHAVIOR; BRAIN; CHEMISTRY; DRUG EFFECTS; METABOLISM; SPRAGUE DAWLEY RAT; STEREOISOMERISM;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; MALE; METHAMPHETAMINE; MOTOR ACTIVITY; NEUROTRANSMITTER AGENTS; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84920861111     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12951     Document Type: Article

References (55)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170:1459-1581.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Transporters. Br J Pharmacol 170: 1706-1796.
3. Arnold EB, Molinoff PB, Rutledge CO (1977). The release of endogenous norepinephrine and dopamine from cerebral cortex by amphetamine. J Pharmacol Exp Ther 202: 544-557.
4. Bauer CT, Banks ML, Blough BE, Negus SS (2013). Use of intracranial self-stimulation to evaluate abuse-related and abuse-limiting effects of monoamine releasers in rats. Br J Pharmacol 168: 850-862.
5. Baumann MH, Ayestas MA, Partilla JS, Sink JR, Shulgin AT, Daley PF et al. (2012). The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37: 1192-1203.
6. Baumann MH, Bulling S, Benaderet TS, Saha K, Ayestas MA, Partilla JS et al. (2014). Evidence for a role of transporter-mediated currents in the depletion of brain serotonin induced by serotonin transporter substrates. Neuropsychopharmacology 39: 1355-1365.
7. Bonano JS, Glennon RA, De Felice LJ, Banks ML, Negus SS (2013). Abuse-related and abuse-limiting effects of methcathinone and the synthetic 'bath salts' cathinone analogs methylenedioxypyrovalerone (MDPV), methylone and mephedrone on intracranial self-stimulation in rats. Psychopharmacology (Berl) 231: 199-207.
8. Brandt SD, Sumnall HR, Measham F, Cole J (2010). Analyses of second-generation 'legal highs' in the UK: initial findings. Drug Test Anal 2: 377-382.
9. Brunt TM, Poortman A, Niesink RJ, van den Brink W (2011). Instability of the ecstasy market and a new kid on the block: mephedrone. J Psychopharmacol 25: 1543-1547.
10. Carroll FI, Lewin AH, Mascarella SW, Seltzman HH, Reddy PA (2012). Designer drugs: a medicinal chemistry perspective. Ann N Y Acad Sci 1248: 18-38.
11. De Deurwaerdère P, Navailles S, Berg KA, Clarke WP, Spampinato U (2004). Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J Neurosci 24: 3235-3241.
12. Deluca P, Schifano F, Davey Z, Corazza O, Di Furia L, the Psychonaut Web Mapping Research Group (2009). Mephedrone Report. Institute of Psychiatry, King's College London: London.
13. Eshleman AJ, Wolfrum KM, Hatfield MG, Johnson RA, Murphy KV, Janowsky A (2013). Substituted methcathinones differ in transporter and receptor interactions. Biochem Pharmacol 85: 1803-1815.
14. Gatch MB, Taylor CM, Forster MJ (2013). Locomotor stimulant and discriminative stimulus effects of 'bath salt' cathinones. Behav Pharmacol 24: 437-447.
15. Glennon RA (2014). Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention. Adv Pharmacol 69: 581-620.
16. Glennon RA, Young R, Martin BR, Dal Cason TA (1995). Methcathinone ('cat'): an enantiomeric potency comparison. Pharmacol Biochem Behav 50: 601-606.
17. Gregg RA, Tallarida CS, Reitz A, McCurdy C, Rawls SM (2013a). Mephedrone (4-methylmethcathinone), a principal component in psychoactive bath salts, produces behavioral sensitization in rats. Drug Alcohol Depend 133: 746-750.
18. Gregg RA, Tallarida CS, Reitz AB, Rawls SM (2013b). Mephedrone interactions with cocaine: prior exposure to the 'bath salt' constituent enhances cocaine-induced locomotor activation in rats. Behav Pharmacol 24: 684-688.
19. Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC et al. (2011). 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 339: 530-536.
20. Hiramatsu M, Cho AK (1990). Enantiomeric differences in the effects of 3,4-methylenedioxymethamphetamine on extracellular monoamines and metabolites in the striatum of freely-moving rats: an in vivo microdialysis study. Neuropharmacology 29: 269-275.
21. Huang M, Dai J, Meltzer HY (2011). 5-HT(2A) and 5-HT(2C) receptor stimulation are differentially involved in the cortical dopamine efflux-studied in 5-HT(2A) and 5-HT(2C) genetic mutant mice. Eur J Pharmacol 652: 40-45.
22. Ikemoto S, Panksepp J (1999). The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking. Brain Res Brain Res Rev 31: 6-41.
23. Johnson MP, Hoffman AJ, Nichols DE (1986). Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. Eur J Pharmacol 132: 269-276.
24. Kalix P (1986). The releasing effect of the isomers of the alkaloid cathinone at central and peripheral catecholamine storage sites. Neuropharmacology 25: 499-501.
25. Kehr J, Ichinose F, Yoshitake S, Goiny M, Sievertsson T, Nyberg F et al. (2011). Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br J Pharmacol 164: 1949-1958.
26. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
27. Kuczenski R, Segal DS, Cho AK, Melega W (1995). Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci 15: 1308-1317.
28. LeBelle MJ, Savard C, Dawson BA, Black DB, Katyal LK, Zrcek F et al. (1995). Chiral identification and determination of ephedrine, pseudoephedrine, methamphetamine and methcathinone by gas chromatography and nuclear magnetic resonance. Forensic Sci Int 71: 215-223.
29. Lisek R, Xu W, Yuvasheva E, Chiu YT, Reitz AB, Liu-Chen LY et al. (2012). Mephedrone ('bath salt') elicits conditioned place preference and dopamine-sensitive motor activation. Drug Alcohol Depend 126: 257-262.
30. López-Arnau R, Martínez-Clemente J, Pubill D, Escubedo E, Camarasa J (2012). Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone. Br J Pharmacol 167: 407-420.
31. Martínez-Clemente J, López-Arnau R, Carbó M, Pubill D, Camarasa J, Escubedo E (2013). Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics. Psychopharmacology (Berl) 229: 295-306.
32. McElrath K, O'Neill C (2011). Experiences with mephedrone pre-and post-legislative controls: perceptions of safety and sources of supply. Int J Drug Policy 22: 120-127.
33. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
34. McKenna DJ, Guan XM, Shulgin AT (1991). 3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine. Pharmacol Biochem Behav 38: 505-512.
35. Meyer A, Mayerhofer A, Kovar KA, Schmidt WJ (2002). Rewarding effects of the optical isomers of 3,4-methylenedioxy-methylamphetamine ('ecstasy') and 3,4-methylenedioxyethylamphetamine ('eve') measured by conditioned place preference in rats. Neurosci Lett 330: 280-284.
36. Motbey CP, Hunt GE, Bowen MT, Artiss S, McGregor IS (2012). Mephedrone (4-methylmethcathinone, 'meow'): acute behavioural effects and distribution of Fos expression in adolescent rats. Addict Biol 17: 409-422.
37. Motbey CP, Clemens KJ, Apetz N, Winstock AR, Ramsey J, Li KM et al. (2013). High levels of intravenous mephedrone (4-methylmethcathinone) self-administration in rats: neural consequences and comparison with methamphetamine. J Psychopharmacol 27: 823-836.
38. Navailles S, Moison D, Cunningham KA, Spampinato U (2008). Differential regulation of the mesoaccumbens dopamine circuit by serotonin2C receptors in the ventral tegmental area and the nucleus accumbens: an in vivo microdialysis study with cocaine. Neuropsychopharmacology 33: 237-246.
39. Negus SS, Miller LL (2014). Intracranial self-stimulation to evaluate abuse potential of drugs. Pharmacol Rev 66: 869-917.
40. Opacka-Juffry J, Pinnell T, Patel N, Bevan M, Meintel M, Davidson C (2014). Stimulant mechanisms of cathinones - Effects of mephedrone and other cathinones on basal and electrically evoked dopamine efflux in rat accumbens brain slices. Prog Neuropsychopharmacol Biol Psychiatry 54: 122-130.
41. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
42. Roberts DC, Koob GF, Klonoff P, Fibiger HC (1980). Extinction and recovery of cocaine self-administration following 6-hydroxydopamine lesions of the nucleus accumbens. Pharmacol Biochem Behav 12: 781-787.
43. Robinson JE, Agoglia AE, Fish EW, Krouse MC, Malanga CJ (2012). Mephedrone (4-methylmethcathinone) and intracranial self-stimulation in C57BL/6J mice: comparison to cocaine. Behav Brain Res 234: 76-81.
44. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI et al. (2001). Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39: 32-41.
45. Rothman RB, Vu N, Partilla JS, Roth BL, Hufeisen SJ, Compton-Toth BA et al. (2003). In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates. J Pharmacol Exp Ther 307: 138-145.
46. Schifano F, Albanese A, Fergus S, Stair JL, Deluca P, Corazza O et al. (2011). Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues. Psychopharmacology (Berl) 214: 593-602.
47. Shortall SE, Macerola AE, Swaby RT, Jayson R, Korsah C, Pillidge KE et al. (2012). Behavioural and neurochemical comparison of chronic intermittent cathinone, mephedrone and MDMA administration to the rat. Eur Neuropsychopharmacol 23: 1085-1095.
48. Sparago M, Wlos J, Yuan J, Hatzidimitriou G, Tolliver J, Dal Cason TA et al. (1996). Neurotoxic and pharmacologic studies on enantiomers of the N-methylated analog of cathinone (methcathinone): a new drug of abuse. J Pharmacol Exp Ther 279: 1043-1052.
49. Timár J, Gyarmati Z, Barna L, Knoll B (1996). Differences in some behavioural effects of deprenyl and amphetamine enantiomers in rats. Physiol Behav 60: 581-587.
50. Tzschentke TM (2007). Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict Biol 12: 227-462.
51. Wang Z, Woolverton WL (2007). Estimating the relative reinforcing strength of (+/?)-3,4-methylenedioxymethamphetamine (MDMA) and its isomers in rhesus monkeys: comparison to (+)-methamphetamine. Psychopharmacology (Berl) 189: 483-488.
52. Winstock A, Mitcheson L, Marsden J (2010). Mephedrone: still available and twice the price. Lancet 376: 1537.
53. Winstock AR, Mitcheson L, Ramsey J, Davies S, Puchnarewicz M, Marsden J (2011a). Mephedrone: use, subjective effects and health risks. Addiction 106: 1991-1996.
54. Winstock AR, Mitcheson LR, Deluca P, Davey Z, Corazza O, Schifano F (2011b). Mephedrone, new kid for the chop? Addiction 106: 154-161.
55. Wright MJ, Angrish D, Aarde SM, Barlow DJ, Buczynski MW, Creehan KM et al. (2012). Effect of ambient temperature on the thermoregulatory and locomotor stimulant effects of 4-methylmethcathinone in Wistar and Sprague-Dawley rats. PLoS ONE 7: e44652.